Jacobson Pharma (HKSE:02633) Total Equity: HK$2,340 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02633 Jacobson Pharma Corp Ltd HKSE:02633
56 GF Score
Price HK$1.04
GF Value HK$0.85
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Jacobson Pharma Total Equity?

Jacobson Pharma HKSE:02633 -0.96% 56 Total Equity is HK$2,340 Mil as of Mar. 2026. GuruFocus rates HKSE:02633 with a GF Score™ of 56/100 and a GF Value™ of HK$0.85 (Modestly Overvalued). The stock has 2 warning signs investors should review.

Jacobson Pharma's total equity for the quarter that ended in Mar. 2026 was HK$2,340 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Jacobson Pharma Total Equity Historical Data

* Premium members only.

The historical data trend for Jacobson Pharma's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jacobson Pharma Total Equity Chart

Jacobson Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,957.97 3,256.52 2,396.36 2,477.44 2,340.21

Jacobson Pharma Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,396.36 2,455.76 2,477.44 2,258.61 2,340.21
HKSE:02633
56GF Score
Jacobson Pharma Corp Ltd HKSE:02633
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jacobson Pharma Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Jacobson Pharma's Total Equity for the fiscal year that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=3563.904-1223.692
=2,340

Jacobson Pharma's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=3563.904-1223.692
=2,340

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of HK$2,340 Mil mean?
Jacobson Pharma (HKSE:02633) has a Total Equity of HK$2,340 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Jacobson Pharma and its competitors.
Is Jacobson Pharma's Total Equity too high?
Jacobson Pharma's current Total Equity is HK$2,340 Mil. Overall, Jacobson Pharma has a GF Score™ of 56/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jacobson Pharma's Total Equity compare to ZTS?
Jacobson Pharma's Total Equity of HK$2,340 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Jacobson Pharma and its competitors. Jacobson Pharma's current Total Equity is HK$2,340 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jacobson Pharma stock overvalued right now?
Based on GuruFocus' analysis, Jacobson Pharma (HKSE:02633) is currently considered Modestly Overvalued. The stock's GF Value™ is HK$0.85, compared to a current price of HK$1.04 — trading 21.8% above its estimated fair value. The current Total Equity is HK$2,340 Mil. Jacobson Pharma's overall GF Score™ is 56/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Jacobson Pharma (HKSE:02633), the current Total Equity is HK$2,340 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jacobson Pharma (HKSE:02633) Overvalued in 2026?

Based on GuruFocus' analysis, Jacobson Pharma stock appears to be overvalued. The current stock price of HK$1.04 is trading 21.8% above its estimated GF Value™ of HK$0.85. GuruFocus considers Jacobson Pharma to be Modestly Overvalued.

Key valuation signals for HKSE:02633:

  • Total Equity: HK$2,340 Mil
  • GF Value™: HK$0.85 vs. price of HK$1.04 (21.8% above fair value)
  • GF Score™: 56/100 with 2 warning signs

No single metric tells the full story. See the HKSE:02633 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Jacobson Pharma Business Description

Address 388 Kwun Tong Road, Unit 2313-18, 23rd Floor, Tower 1, Millennium City 1, Kwun Tong, Kowloon, Hong Kong, HKG
Jacobson Pharma Corp Ltd is an investment holding company. It is principally engaged in the development, production, marketing, and sale of generic drugs. The company's operating segment includes Generic drugs; Branded healthcare, Wholesale, and retail The generic drugs segment develops, manufactures, and distributes a host of off-patent medicines for various therapeutic use. It generates maximum revenue from the Generic drugs segment. Geographically, it derives a majority of its revenue from Hong Kong and also has a presence in Mainland China, Macau, Singapore, and Other Countries.
56GF Score

Get the complete analysis for HKSE:02633

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$1.04
Price
HK$0.85
GF Value